Melbourne Health

Parkville, Australia

Melbourne Health

Parkville, Australia

Time filter

Source Type

"The flexibility of OnBase was central to our decision to select and implement the technology in both clinical and administrative applications, enabling our users to have immediate and secure access to critical information," said Rhonda Carroll, director of information and performance at Melbourne Health. "OnBase is crucial to our current scanning operations and workflow functionalities, and it will be a critical component to our future integration with an EMR." In addition to digitizing health records, OnBase was recently selected to help optimize some payroll functionality in the Finance department at Melbourne Health. "Melbourne Health is a stellar example for healthcare organisations striving to streamline processes and improve patient care," said Susan deCathelineau, vice president, global healthcare sales and services at Hyland. "The smart ways in which they have deployed OnBase now and plans for the future applications will pave the way for successful integrations, which ultimately equal cost savings and benefits to all Melbourne Health stakeholders – most importantly, the patients." To learn why more than 1,800 organizations across the globe are leveraging OnBase technology across the enterprise to digitize health records, streamline back-office functions and provide exemplary patient care, visit OnBase.com/Healthcare. About Hyland Hyland is a leader in providing software solutions for managing content, processes and cases for organizations across the globe. For 25 years, Hyland has enabled more than 15,500 organizations to digitalize their workplaces and fundamentally transform their operations. Named one of Fortune's Best Companies to Work For® since 2014, Hyland is widely known as both a great company to work for and a great company to do business with. For more information, please visit Hyland.com. About OnBase by Hyland OnBase is a single enterprise information platform for managing content, processes and cases deployed via mobile, on-premises or in the Hyland Cloud. Providing enterprise content management (ECM), case management, business process management (BPM), records management and capture all on a single platform, OnBase transforms organizations around the globe by empowering them to become more agile, efficient and effective. Enterprise cloud-based sharing capability for the OnBase platform is available with our complementary offering, ShareBase by Hyland. Over 1,800 healthcare organizations use OnBase to complete patient records, eliminate reimbursement delays and enhance business processes. Dedicated to meeting the evolving needs of our customers for document and process management, OnBase has evolved through consistent product innovation and remains focused on automating business processes that depend on documents, content and people to operate more effectively. For more information about OnBase, visit OnBase.com/Healthcare. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/onbase-by-hyland-supports-melbourne-health-in-clinical-and-administrative-applications-300463189.html


Patent
Melbourne Health, Austin Health and Southern Health | Date: 2011-05-11

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents an in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.


Patent
Melbourne Health, Austin Health and Southern Health | Date: 2012-05-23

The present invention relates to methods for determining the potential of hepatitis B virus, HBV, variants to exhibit reduced sensitivity to Adefovir dipivoxil, ADV, and/or Tenofovir, TFV. The present invention is also directed to isolated HBV variants exhibiting decreased sensitivity to ADV and/or TFV. The present invention further contemplates methods for detecting agents having inhibitory activity to such viral variants, as well as the uses of such viral variants in the rational design of anti-HBV agents and in the manufacture of medicaments for the treatment and/or prophylaxis of HBV infection.


Patent
Melbourne Health, Austin Health, Southern Health, St. Vincents Hospital Melbourne Ltd. trading as St. Vincents Hospital Melbourne and Alfred Health | Date: 2012-01-11

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.


Patent
Csiro, Walter, Eliza Hall Institute of Medical Research, Grains Research And Development Corporation and Melbourne Health | Date: 2015-09-02

The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliacs disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.


Patent
Grains Research And Development Corporation, Walter, Eliza Hall Institute of Medical Research, Csiro and Melbourne Health | Date: 2014-01-28

The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliacs disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.


Patent
Melbourne Health | Date: 2011-08-24

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants.


To estimate the risk of active tuberculosis (TB) in immigrants to VICtoria, Australia, as a function of time since arrival and stratified by age group and region of origin. DESIGN, SETTING AND SUBJECT: Longitudinal study of the incidence of active TB in VICtorian immigrants, excluding New Zealanders, who arrived in Australia between 1975 and 2007. VICtorian immigration data were used to describe annual arrival cohorts by age and region of origin, and TB case notification data for 1995 to 2010 were matched to the cohorts. Survival analysis was performed to determine incidence rates of active TB. Incidence of active TB, stratified by age, region of origin and time since arrival in Australia. Incidence of active TB following immigration to Australia was highly dependent on region of origin, with the highest risks being in immigrants from South Asia and sub-Saharan Africa. For immigrants from high-risk regions (Asia, Africa and the Pacific), the incidence of active TB infection was 100-150 per 100 000 person-years in the first 6 years following immigration. Overall, we estimate that 50% of TB occurred within 7 years of arrival. A bimodal age distribution was evident, with peaks of incidence in 20-24-year-olds and 70-74-year-olds. Our data show that substantial risk of TB in VICtorian immigrants persists well beyond the first 2-3 years following arrival, and that risk is highly dependent on region of origin. The regional dependence suggests that public health strategies would benefit from more refined regional stratification of risk, which could be used to determine risk thresholds for the use of TB prevention strategies and predict rates of TB in Australia following particular patterns of immigration.


Patent
Melbourne Health, Austin And Repatriation Medical Center and Central Sydney Area Health Service | Date: 2011-08-24

The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.


Patent
Melbourne Health | Date: 2012-07-12

The present invention relates generally to viral variants exhibiting reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic agents.

Loading Melbourne Health collaborators
Loading Melbourne Health collaborators